Sienna Biopharmaceuticals has announced positive results from its trial of SNA-001 in conjunction with an 810 nm Diode laser, which involved 65 patients.
Sienna said that its SNA-001 is a study which involved topical pre-treatment to standard laser hair removal in men and women with white, gray, blonde, light red and light brown hair.
Data from the trial showed that the study has met the primary endpoint of non-inferiority in hair reduction with -17.5% with SNA-001+Laser compared to -1.1% with vehicle+Laser following six treatment sessions.
Additional analyses also showed that SNA-001 was statistically higher compared to vehicle+Laser, and is claimed to reduce up to 31% of light hair from baseline.
SNA-001 uses silver particles applied to the skin to harness light energy from a medical laser to target the hair follicle inside the pilosebaceous unit. This results in reduction of light- and non-pigmented hair.
SNA-001 is a topical, ready-to-use suspension applied to the treatment area on the skin and it is delivered into the pores. The silver particles are then activated by a laser to thermally target the hair follicle while surrounding tissue is spared. This process is called selective photothermolysis. The silver particles in SNA-001 are claimed to have been designed to work with common lasers already used in aesthetic clinics and laser centers.
Sienna Biopharmaceuticals president and CEO Frederick C. Beddingfield III said: “SNA-001 represents an exciting growth opportunity for the aesthetics market, and a potential solution for consumers with light hair who are well aware of the ineffectiveness of laser hair removal. We are pleased with these results and will seek a strategic partner who can rapidly maximize the value of SNA-001.
“This will allow us to remain focused on our Phase 3 development of SNA-120, our TrkA inhibitor for psoriasis and pruritus, and to unlock the full potential of our Topical by Design platform, from which we are creating a pipeline of drug candidates that target select pathways in specific tissues to treat a variety of chronic inflammatory and immunologic conditions.”
Laser hair removal, which has been around for nearly 25 years, is one of the most commonly performed aesthetic procedures. More than 12 million procedures are done every year in the US alone.
But, people with white, gray, blonde and red hair, have been limited to using waxing and razors for hair removal, as for whom lasers are ineffective.
As per Sienna Biopharmaceuticals’ data, a safe and effective treatment for people with light hair could increase the number of laser hair removal procedures by 27% in the US.